Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

Extracellular vesicles shed by prostate cancer cells to the bloodstream contain tumor-derived material that can be used as biomarkers of therapy response and resistance in patients with metastatic ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about navigating treatment option in prostate cancer. Advancements in prostate ...

Scientists report landmark "evolutionary double-bind" strategy to overcome treatment resistance in prostate cancer.

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 ...

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...

If you or a loved one has prostate cancer, you may be interested in learning about medicines used to treat it. One option is a medicine called Erleada (apalutamide). The FDA approved Erleada in 2018.

For people battling prostate cancer, the fight can feel like a contest between the disease and the doctors. Their body is the battlefield, but they may nonetheless feel marginalized—more bystander ...